Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG
about
The use of flow cytometry to assess a novel drug efficacy in multiple sclerosisRTL551 treatment of EAE reduces CD226 and T-bet+ CD4 T cells in periphery and prevents infiltration of T-bet+ IL-17, IFN-γ producing T cells into CNSBinding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis.Characterization of human platelet binding of recombinant T cell receptor ligand.Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis.Protection of Tregs, suppression of Th1 and Th17 cells, and amelioration of experimental allergic encephalomyelitis by a physically-modified saline.Recombinant T cell receptor ligands improve outcome after experimental cerebral ischemia.Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study.A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerancePeptide-MHC-based nanovaccines for the treatment of autoimmunity: a "one size fits all" approach?Neuroimmune pharmacological control of EAE.Uncovering the Rosetta Stone: Report from the First Annual Conference on Key Elements in Translating Stroke Therapeutics from Pre-Clinical to Clinical.
P2860
Q26824619-5A7F3F51-5A30-4D4E-8BE0-9AA6164A062EQ28742932-B6B62C07-008D-437A-98EA-0A9AFB437D70Q34077153-B7D2C28A-5D35-4FCC-BBDE-6868CA5EBF71Q34350992-83160A38-69C8-4D27-881A-8A0C8AB819CCQ34476372-23FBF2ED-D88A-4C05-B0DB-CFBE8ED90A52Q34532426-531AF487-14D9-435A-A3E9-17EB08FA1BA2Q35234869-03D74091-34F7-4ACD-808B-4134B702FDB9Q35893543-5FEB96B2-7DCE-400F-A6C5-FE8A19C669ADQ37212157-81D5E3BD-4D35-41AD-8E20-76A5D445D397Q37866131-EDECE39E-6EBE-486A-B89B-180B279783B5Q40898464-6672E7F0-1DFA-4765-A031-18EF5EE5C838Q52597283-E1E14382-B31A-4F79-B7C7-9D681D584A05
P2860
Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Recombinant TCR ligand reverse ...... duced by recombinant human MOG
@ast
Recombinant TCR ligand reverse ...... duced by recombinant human MOG
@en
type
label
Recombinant TCR ligand reverse ...... duced by recombinant human MOG
@ast
Recombinant TCR ligand reverse ...... duced by recombinant human MOG
@en
prefLabel
Recombinant TCR ligand reverse ...... duced by recombinant human MOG
@ast
Recombinant TCR ligand reverse ...... duced by recombinant human MOG
@en
P2093
P2860
P1476
Recombinant TCR ligand reverse ...... duced by recombinant human MOG
@en
P2093
Arthur A Vandenbark
Ashley Emerson-Webber
Christopher Linington
Claude C A Bernard
Gregory G Burrows
Halina Offner
Maren Lindner
Marjorie Grafe
Sandhya Subramanian
Sushmita Sinha
P2860
P2888
P304
P356
10.1007/S11481-009-9175-1
P577
2009-09-30T00:00:00Z
P5875
P6179
1040268193